Abstract
Levetiracetam is an antiepileptic drug approved for use by the US FDA as adjunctive therapy in partial-onset seizures in adults and children 4 years or older. It has also been approved as adjunctive treatment for adults and children 12 years and over with juvenile myoclonic epilepsy and for the treatment of primary generalized tonic–clonic seizures in adults and children over the age of 6 years with idiopathic generalized epilepsy. In Europe, in addition to these indications, it is also approved for use as monotherapy in the treatment of partial-onset seizures in patients from the age of 16 years with newly diagnosed epilepsy. It has a unique mechanism of action different to that of other antiepileptic drugs. The recent development of a parenteral intravenous formulation allows for its use when oral administration is not feasible. The most common serious side effects in children are behavioral. Its broad spectrum of action, lack of significant systemic side effects and the absence of interaction with other drugs makes it an attractive choice for use in children with epilepsy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
